cardiogenic shock

15 · 20 / page

Ask MedXY AI

Latest news

Tag

Cardiologycardiogenic shockdobutamine

Cardiogenic Shock Care Still Varies Widely Across CICUs, Especially in the Choice of Inodilators

By MedXY|May 19, 2026

A large CCCTN analysis found major institutional and patient-level variation in vasoactive drug selection for cardiogenic shock, highlighting persistent evidence gaps in choosing dobutamine, milrinone, and other vasoactive therapies.

Circulatory Support Escalation in Cardiogenic Shock: Outcomes and Predictors of Success

Cardiologycardiogenic shockcirculatory support

cardiogenic shock

Latest news

Cardiogenic Shock Care Still Varies Widely Across CICUs, Especially in the Choice of Inodilators

Circulatory Support Escalation in Cardiogenic Shock: Outcomes and Predictors of Success

Transfer Before Support: Why Cardiogenic Shock Patients Referred from Regional Centers Face Higher Device-Related Complications

Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock

The Warning Signs of Deterioration: Acute Kidney Injury and Diuretic Resistance in SCAI Stage B Cardiogenic Shock

AKI and Diuretic Resistance: Identifying the High-Risk Phenotype in SCAI Stage B Cardiogenic Shock

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock

Beyond the DanGer Shock Trial: Real-World Outcomes and Risk Stratification in Impella-Treated Patients

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

C-Reactive Protein as a Prognostic Biomarker in Infarct-Related Cardiogenic Shock: Insights from the ECLS-SHOCK Trial